Neuland Laboratories Past Earnings Performance
Past criteria checks 6/6
Neuland Laboratories has been growing earnings at an average annual rate of 53.8%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 16% per year. Neuland Laboratories's return on equity is 28%, and it has net margins of 20.1%.
Key information
53.8%
Earnings growth rate
53.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 16.0% |
| Return on equity | 28.0% |
| Net Margin | 20.1% |
| Next Earnings Update | 10 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Neuland Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 15,809 | 3,171 | 2,449 | 0 |
| 30 Sep 23 | 14,574 | 2,662 | 2,308 | 0 |
| 30 Jun 23 | 13,333 | 2,154 | 2,142 | 0 |
| 31 Mar 23 | 11,915 | 1,635 | 2,026 | 0 |
| 31 Dec 22 | 10,406 | 1,008 | 1,969 | 0 |
| 30 Sep 22 | 10,078 | 831 | 1,934 | 0 |
| 30 Jun 22 | 9,720 | 651 | 1,884 | 0 |
| 31 Mar 22 | 9,517 | 638 | 1,832 | 0 |
| 31 Dec 21 | 9,400 | 593 | 1,826 | 0 |
| 30 Sep 21 | 9,489 | 731 | 1,725 | 0 |
| 30 Jun 21 | 9,324 | 742 | 1,589 | 0 |
| 31 Mar 21 | 9,370 | 806 | 1,505 | 0 |
| 31 Dec 20 | 8,852 | 540 | 1,400 | 0 |
| 30 Sep 20 | 8,436 | 384 | 1,331 | 0 |
| 30 Jun 20 | 7,884 | 257 | 1,292 | 0 |
| 31 Mar 20 | 7,640 | 162 | 1,242 | 0 |
| 31 Dec 19 | 7,443 | 321 | 1,216 | 0 |
| 30 Sep 19 | 7,120 | 257 | 1,192 | 0 |
| 30 Jun 19 | 6,945 | 216 | 1,155 | 0 |
| 31 Mar 19 | 6,675 | 164 | 1,130 | 0 |
| 31 Mar 18 | 5,284 | 121 | 1,055 | 0 |
| 31 Mar 17 | 5,789 | 469 | 1,010 | 0 |
| 31 Mar 16 | 5,100 | 273 | 847 | 0 |
| 31 Mar 15 | 4,692 | 159 | 645 | 0 |
| 31 Mar 14 | 4,657 | 268 | 815 | 108 |
Quality Earnings: 524558 has high quality earnings.
Growing Profit Margin: 524558's current net profit margins (20.1%) are higher than last year (9.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524558's earnings have grown significantly by 53.8% per year over the past 5 years.
Accelerating Growth: 524558's earnings growth over the past year (214.7%) exceeds its 5-year average (53.8% per year).
Earnings vs Industry: 524558 earnings growth over the past year (214.7%) exceeded the Pharmaceuticals industry 23.1%.
Return on Equity
High ROE: 524558's Return on Equity (28%) is considered high.